



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Panitumumab

April 1, 2015

Non-proprietary name

Panitumumab (genetical recombination)

Safety measure

Precautions should be revised in the package insert.

In the Precautions of Indications section, the following texts should be deleted:

‘The efficacy have not been established in patients with KRAS mutation’

The following texts should be added (underlined parts are revised):

Prior to initiation of treatment, assess RAS (KRAS and NRAS) mutation status and select a suitable patient.